PMID- 26558012
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20151111
LR  - 20200930
IS  - 2090-598X (Print)
IS  - 2090-5998 (Electronic)
IS  - 2090-598X (Linking)
VI  - 10
IP  - 2
DP  - 2012 Jun
TI  - Prognostic markers in renal cell carcinoma: A focus on the 'mammalian target of 
      rapamycin' pathway.
PG  - 110-7
LID - 10.1016/j.aju.2012.02.005 [doi]
AB  - OBJECTIVES: Increased knowledge about the molecular pathways involved in 
      tumorigenesis has led to the discovery of new prognostic molecular markers and 
      development of novel targeted therapies for renal cell carcinoma (RCC). In this 
      review we describe the prognostic markers of RCC and highlight the areas of 
      recent discovery with a focus on the mammalian target of rapamycin (mTOR) 
      pathway. METHODS: We reviewed previous reports, using PubMed with the search 
      terms 'renal cell carcinoma', 'molecular markers', 'prognosis', 'outcomes' and 
      'mammalian target of rapamycin pathway' published in the last two decades. We 
      created a library of 100 references and focused on presenting the recent advances 
      in the field. RESULTS: Growing evidence suggests that mTOR deregulation is 
      associated with many types of human cancer, including RCC. Consequently, 
      temsirolimus and everolimus, which target mTOR, are approved for treating 
      advanced RCC. There is a demand to integrate clinical, pathological and molecular 
      markers into accurate prognostic models to provide patients with the most 
      personalised cancer care possible. CONCLUSIONS: The mTOR pathway is highly 
      implicated in RCC tumorigenesis and progression, and its constituents might 
      represent a promising prognostic tool and target for treating RCC. Combining 
      newly discovered molecular markers with classic clinicopathological prognostics 
      might potentially improve the management of RCC.
FAU - Youssef, Ramy F
AU  - Youssef RF
AD  - Division of Urologic Oncology, University of Texas Southwestern Medical Center, 
      Dallas, TX, USA.
FAU - Cost, Nicholas G
AU  - Cost NG
AD  - Division of Urologic Oncology, University of Texas Southwestern Medical Center, 
      Dallas, TX, USA.
FAU - Darwish, Oussama M
AU  - Darwish OM
AD  - Division of Urologic Oncology, University of Texas Southwestern Medical Center, 
      Dallas, TX, USA.
FAU - Margulis, Vitaly
AU  - Margulis V
AD  - Division of Urologic Oncology, University of Texas Southwestern Medical Center, 
      Dallas, TX, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20120409
PL  - United States
TA  - Arab J Urol
JT  - Arab journal of urology
JID - 101562480
PMC - PMC4442886
OTO - NOTNLM
OT  - 4E-BP1, eukaryotic initiation factor-binding protein-1
OT  - CA-9, carbonic anhydrase 9
OT  - HIF, hypoxia inducible factor
OT  - IRS-1, insulin receptor substrate-1
OT  - LDH, lactate dehydrogenase
OT  - Molecular markers
OT  - PI3k, phosphatidylinositol 3-kinase
OT  - Prognostic
OT  - Renal cell carcinoma
OT  - S6K1, S6 kinase 1
OT  - TKR, tyrosine kinase receptor
OT  - TSC, tuberous sclerosis complex
OT  - VEGF, vascular endothelial growth factor
OT  - VHL, von Hippel-Lindau
OT  - mTOR
OT  - mTOR, mammalian target of rapamycin
EDAT- 2012/06/01 00:00
MHDA- 2012/06/01 00:01
PMCR- 2012/04/09
CRDT- 2015/11/12 06:00
PHST- 2012/02/01 00:00 [received]
PHST- 2012/02/23 00:00 [revised]
PHST- 2012/02/25 00:00 [accepted]
PHST- 2015/11/12 06:00 [entrez]
PHST- 2012/06/01 00:00 [pubmed]
PHST- 2012/06/01 00:01 [medline]
PHST- 2012/04/09 00:00 [pmc-release]
AID - S2090-598X(12)00040-X [pii]
AID - 10.1016/j.aju.2012.02.005 [doi]
PST - ppublish
SO  - Arab J Urol. 2012 Jun;10(2):110-7. doi: 10.1016/j.aju.2012.02.005. Epub 2012 Apr 
      9.